Search

Displaying results 3541 - 3550 of 7687 in total
  1. Drug

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10800
    ApprovedInvestigational

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  2. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    Pramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470].

  3. Drug

    Chlorquinaldol

    go.drugbank.com/drugs/DB13306
    Approved

    [F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones.

  4. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.

  5. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine.

  6. Drug

    Acetylcholine

    go.drugbank.com/drugs/DB03128
    ApprovedInvestigational

    It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.

  7. Drug

    Phenylacetic acid

    go.drugbank.com/drugs/DB09269
    Approved

    Phenylacetic acid is an organic compound containing a phenyl functional group and a carboxylic acid functional group. It is a white solid with a disagreeable odor.

  8. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor

  9. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma

  10. Drug

    CAN-106

    go.drugbank.com/drugs/DB18389
    Investigational

    CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.